糖尿病管理中胰岛素选择策略
本文综述了胰岛素治疗在1型和2型糖尿病中的应用,指出严重高血糖或分解代谢状态患者应起始胰岛素,HbA1c>10%或1型糖尿病诊断不明者通常需胰岛素治疗。胰岛素产品主要区别在于药代动力学而非作用机制,不同药代动力学特征可应对类固醇性高血糖、严重慢性肾脏病或透析及胰岛素泵治疗等临床情况。
要点
- 严重高血糖或体重下降、酮尿等分解代谢状态患者应起始胰岛素治疗。
- HbA1c>10%或1型糖尿病诊断不明确者通常需胰岛素治疗。
- 胰岛素产品差异主要在药代动力学,可据此选择以覆盖空腹或餐时血糖。
核心结论
- 了解不同胰岛素制剂的动力学特征有助于临床医生合理选择空腹或餐时覆盖方案。
- 这一基础知识在类固醇性高血糖、肾脏疾病和胰岛素泵管理等临床场景中应用胰岛素治疗时至关重要。
研究设计与样本
- 证据获取:纳入人群水平数据,检索PubMed和Google Scholar数据库中的近期系统综述、Meta分析和原始研究文章。
主要发现
- 出现严重高血糖或体重下降、酮尿等分解代谢状态体征的患者应起始胰岛素治疗。
- 血红蛋白A1c(HbA1c)水平>10%或1型糖尿病诊断不明确的患者通常应接受胰岛素治疗。
- 胰岛素产品主要区别在于药代动力学特征而非作用机制。
- 文献提示药代动力学差异使某些胰岛素产品能很好应对类固醇性高血糖、严重慢性肾脏病或透析患者管理及胰岛素泵治疗等不同临床情况。
临床怎么用
- 临床医生应理解不同胰岛素制剂的动力学特征,以合理选择空腹或餐时覆盖方案。
- 在类固醇性高血糖、肾脏疾病和胰岛素泵管理等临床场景中应用胰岛素治疗时,这一基础知识至关重要。
- 最终使临床医生和患者能够制定适当的糖尿病护理计划和自我管理技能。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Insulin therapy is first-line therapy for people with type 1 diabetes and often used for people with type 2 diabetes. Over the years, there has been a surge in insulin products available for use. As a result, clinicians need to have a strong understanding of the differences between insulin agents to provide proper patient care. EVIDENCE ACQUISITION: We included population-level data and searched PubMed and Google Scholar databases for recent systematic reviews, meta-analyses, and original research articles. EVIDENCE SYNTHESIS: Patients who present with severe hyperglycemia or signs consistent with a catabolic state such as weight loss or ketonuria should be initiated on insulin. Furthermore, patients with a hemoglobin A1c (HbA1c) level >10% or an unclear diagnosis of type 1 diabetes should typically be treated with insulin. Insulin products differ mainly in their pharmacokinetic profiles and not mechanism of action. The literature suggests that differences in pharmacokinetics allow certain insulin products to be well equipped to address different clinical situations such as steroid-induced hyperglycemia, managing patients with severe chronic kidney disease or dialysis, and insulin pump therapy. CONCLUSION: Understanding kinetic profiles of different insulin agents will allow clinicians to properly navigate options for either fasting or mealtime coverage. Furthermore, this foundational knowledge will be critical when applying insulin therapy in clinical scenarios such as steroid-induced hyperglycemia, kidney disease, and insulin pump management. Ultimately, this will allow clinicians and patients to create proper diabetes care plans and self-management skills.
引用
- Rafi E, Tranchito L, Hatipoglu B, et al. Navigating Insulin Options for Diabetes Management. J Clin Endocrinol Metab. 2025. PMID: 39998925. doi:10.1210/clinem/dgae790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。